Relationship between CD4 + T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue 1, 2010, Pages 117-127

  Smurzynski, Marlene ^a   Wu, Kunling ^a   Benson, Constance A ^b   Bosch, Ronald J ^a   Collier, Ann C ^c   Koletar, Susan L ^d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

CD4 cell counts; HIV; Opportunistic infections; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE BRAIN DISEASE; ADULT; ARTICLE; BACTERIAL INFECTION; BEHAVIOR; BODY MASS; BRAIN LYMPHOMA; BRONCHITIS; BURKITT LYMPHOMA; CANDIDIASIS; CD4 LYMPHOCYTE COUNT; COCCIDIOIDOMYCOSIS; COMORBIDITY; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOSPORIDIOSIS; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS RETINITIS; DEMOGRAPHY; ESOPHAGITIS; FEMALE; HERPES SIMPLEX; HISTOPLASMOSIS; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOBLASTIC LYMPHOMA; INCIDENCE; INFECTION PREVENTION; ISOSPORIASIS; KAPOSI SARCOMA; LOGISTIC REGRESSION ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; MYCOBACTERIUM KANSASII; MYCOSIS; PARASITOSIS; PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL; RISK; RNA VIRUS; SEPTICEMIA; TOXOPLASMOSIS; TUBERCULOSIS; ULCER; UTERINE CERVIX CANCER; VIRUS LOAD; VISUAL IMPAIRMENT; WASTING SYNDROME; ADOLESCENT; AGED; BLOOD; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNOLOGY; ISOLATION AND PURIFICATION; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RISK FACTOR; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV-1; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; RNA, VIRAL; VIRAL LOAD; YOUNG ADULT;

EID: 77956645721     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181e8c129     Document Type: Article

References (31)

1. Brodt HR, Kamps BS, Gute P, et al. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS. 1997;11:1731-1738. (Pubitemid 27470275)
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860. (Pubitemid 28135961)
3. Gebo KA, Fleishman JA, Moore RD, et al. Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV-patients; trends between 1996 and 2000 in 12 states. J Acquir Immune Defic Syndr. 2005;40:609-616. (Pubitemid 41669167)
4. CASCADE Collaboration. Effective therapy has altered the spectrum of cause specific mortality following HIV seroconversion. AIDS. 2006;20:741-749.
5. Buchacz K, Baker RK, Moorman AC, et al, and the HIV Outpatient Study (HOPS) Investigators. Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005. AIDS. 2008;22:1345-1356.
6. Neuhaus J, Angus B, Kowalska JD, et al, and INSIGHT SMART and ESPRIT Study Groups. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS. 2010;24:697-706.
7. Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS. 2009;23:41-50.
8. Koletar SL, Williams PL, Wu J, et al, and AIDS Clinical Trials Group 362 Study Team. Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapy. Clin Infect Dis. 2004;39:1500-1506. (Pubitemid 39518215)
9. Baker JV, Peng G, Rapkin J, et al, and Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008;22:841-848. (Pubitemid 351563833)
10. Brooks JT, Kaplan JE, Holmes KK, et al. HIV-associated opportunistic infections-going, going, but not gone: the continued need for prevention and treatment guidelines. Clin Infect Dis. 2009;48:609-611.
11. Egger M, May M, Chêne G, et al, and ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129. (Pubitemid 34786200)
12. Torti C, Lapadula G, Maggiolo F, et al, and Italian MASTER Cohort. Predictors of AIDS-defining events among advanced naive patients after HAART. HIV Clin Trials. 2007;8:112-120. (Pubitemid 47134648)
13. 3. Antivir Ther. 2007;12:941-947. (Pubitemid 47492563)
14. Chêne G, Sterne JA, May M, et al, and Antiretroviral Therapy Cohort Collaboration. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 2003;362:679-686.
15. MacArthur RD, Perez G, Walmsley S, et al, and Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) 042/045; Canadian HIV Trials Network (CTN) 102 Protocol Teams. Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy. HIV Clin Trials. 2005;6:127-135. (Pubitemid 41341727)
16. Smurzynski M, Collier AC, Koletar SL, et al. AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics. HIV Clin Trials. 2008;9:269-282.
17. CDC. 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. MMWR. 1992;41(RR-17):1-19.
18. D'Agostino RB, Lee ML, Belanger AJ, et al. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med. 1990;9:1501-1515.
19. Diggle PJ, Liang KY, Zeger SL. Analysis of Longitudinal Data. New York, NY: Oxford University Press; 1994.
20. Sullivan PS, Denniston M, McNaghten A, et al. Use of a population-based survey to determine incidence of AIDS-defining opportunistic illnesses among HIV-positive persons receiving medical care in the United States. AIDS Res Ther. 2007;4:17.
21. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA. 1999;282:2220-2226. (Pubitemid 30002965)
22. Podlekareva D, Mocroft A, Dragsted UB, et al, and EuroSIDA study group. Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study. J Infect Dis. 2006;194:633-641. E-pub: July 24, 2006. (Pubitemid 44297849)
23. Schacker TW, Reilly C, Beilman GJ, et al. Amount of lymphatic tissue fibrosis in HIV infection predicts magnitude of HAART-associated change in peripheral CD4 cell count. AIDS. 2005;19:2169-2171. (Pubitemid 41669008)
24. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534-1543. E-pub April 23, 2003. (Pubitemid 36578959)
25. Giorgi JV, Lyles RH, Matud JL, et al, and Multicenter AIDS Cohort Study. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr. 2002;29:346-355. (Pubitemid 34288887)
26. Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother. 2006;57:167-170. (Pubitemid 43160154)
27. Centers for Disease Control and Prevention. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep. 2009 Sep. 4;58(RR-11):1-166.
28. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis. 2005;5:361-373. (Pubitemid 40779257)
29. Heffelfinger JD, Voetsch AC, Nakamura GV, et al. Nonadherence to primary prophylaxis against Pneumocystis jirovecii pneumonia. LPLoS One. 2009;4:e5002. E-pub March 25, 2009.
30. Lederman HM, Williams PL, Wu JW, et al, and AIDS Clinical Trials Group 889 Study Team. Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virusinfected patients with severe CD4+ cell depletion. J Infect Dis. 2003;188:1794-1803. (Pubitemid 38064863)
31. Robbins GK, Spritzler JG, Chan ES, et al, and the AIDS Clinical Trials Group 384. Incomplete reconstitution of T cell subsets on combination antiretroviral therapyin the AIDS clinical trials group protocol 384. Clin Inf Dis. 2009;48:350-361.